Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Get With the Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead

Tang AB, Lewsey SC, Yancy CW, Heidenreich PA, Greene SJ, Allen LA, Jessup M, Bolles M, Rutan C, Navar N, Thomas K, Fonarow GC. Get[...]

Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United States Federally Qualified Health Centers

Zhao MY, Aaronson MRM, Singh V, De Silva SR, Badiee J, May FP. Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United[...]

Validating the Sino-Nasal Outcome Test (SNOT-22) in comparison to the Sino-Nasal 5 Questionnaire (SN-5) in a pediatric population

Cheng MY, Rodriguez DR, Rubio A, Jackson NJ, West AN. Validating the Sino-Nasal Outcome Test (SNOT-22) in comparison to the Sino-Nasal 5 Questionnaire (SN-5) in[...]